3-YEAR RESULTS OF THE PHASE 2 RANDOMIZED TRIAL FOR TALIMOGENE LAHERPAREPVEC (T-VEC) NEOADJUVANT TREATMENT PLUS SURGERY VS SURGERY IN PATIENTS WITH RESECTABLE STAGE IIIB-IVM1A MELANOMA
Reinhard Dummer, David Gyorki, John Hyngstrom, Adam Berger, Robert Conry, Lev Demidov, Edward Chan, Hoi-Shen Radcliffe, Mark Faries, Merrick Ross
Journal for ImmunoTherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2020
The authors thank the investigators, patients, and study staff who are contributing to this study. The study was sponsored and funded by Amgen Inc. Medical writing support was provided by Christopher Nosala (Amgen Inc.).